Literature DB >> 7041592

Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II.

Y Imai, K Abe, M Seino, T Haruyama, J Tajima, K Yoshinaga, H Sekino.   

Abstract

The influence of captopril on pressor responses to exogenously administered vasopressor substances was investigated in normal subjects. Norepinephrine (0.05, 0.1 and 0.2 micrograms/kg . min -1; n = 5), angiotensin II (5, 10 and 20 ng/kg . min -1; n = 5) and vasopressin (2 mU/kg . min -1; n = 5) were infused each for 10 minutes; each infusion was repeated twice. Captopril (50 mg orally) significantly attenuated the pressor response to norepinephrine (0.1 [p less than 0.05], 0.2 [p less than 0.01] micrograms/kg . min -1; n = 7) and to vasopressin (p less than 0.01, n = 5), but not to angiotensin II; these responses were reproducible. Attenuation of the pressor responses to norepinephrine did not occur when a subpressor dose of angiotensin II (ng/kg . min-1) was infused in addition to captopril (n = 5). Infusion of a subpressor dose of bradykinin (0.1 ng/kg . min-1) had no influence on the pressor responses to norepinephrine (n = 5). In the five subjects treated with indomethacin (225 mg/54 hours) captopril still attenuated the pressor responses to norepinephrine. These results suggest that the attenuation by captopril of the pressor responses to norepinephrine and vasopressin might have been due to reduction of endogenous angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7041592     DOI: 10.1016/0002-9149(82)90381-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Effect of captopril on changes in plasma noradrenaline induced by sodium nitroprusside.

Authors:  R H Becker; A D Struthers; M J Brown
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  Enalapril versus combined enalapril and nadolol treatment: effects on blood pressure, heart rate, humoral variables, and plasma potassium at rest and during exercise in hypertensive patients.

Authors:  P A Sullivan; B Daly; R O'Connor
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

Review 4.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 5.  Angiotensin I converting enzyme inhibitors and the renal excretion of urate.

Authors:  W P Leary; A J Reyes
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

Review 6.  Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.

Authors:  R J Cody
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.